Adjuvants for human vaccines;Adjuvanten für humanvakzinen

Pharmazie in Unserer Zeit

Volumn 37, Issue 1, 2008, Pages 42-51

  Bröker, Michael ^a   Beyer, Christine ^a  

^a Novartis Sehring   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INFLUENZA VACCINE; VACCINE; ALUMINUM DERIVATIVE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ARTICLE; HUMAN; IMMUNOPATHOLOGY; INFLUENZA; AGED; AGING; ANIMAL; EMULSION; HISTORY; IMMUNOLOGY; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AGED; AGING; ALUMINUM COMPOUNDS; ANIMALS; EMULSIONS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; VACCINES;

EID: 38349051422     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200700250     Document Type: Article

References (23)

1. Jefferson, T.: A basic glossary of vaccinology. J. Epidemiol. Comm. Health 55 (2001), 294-295.
2. Vogel, F.R., Powell, M. F.: A compendium of vaccine adjuvants and excipients. In: Powell, M. F., Newman, M.J. (eds): Vaccine design: The subunit and adjuvant approach. New York: Plenum Press (1995), pp. 141-228.
3. Haas, R., Thomssen, R.: Über den Entwicklungsstand der in der Immunbiologie gebräuchlichen Adjuvantien. Ergeb. Mikrobiol. Immunitätsforsch, und Exp. Therapie 34 (1960), 27-119.
4. Gupta, R. K., Rost, B. E., Relyveld, E., et al.: Adjuvant properties of aluminium and calcium compound. In: Powell, M. F., Newman, M. J. (eds): Vaccine Design: The subunit and adjuvant approach. New York: Plenum Press (1995), pp. 229-248.
5. Hem, S. L., White, J. L. Structure and properties of aluminium-containing adjuvants, In: Powell, M. F., Newman, M.J. (eds): Vaccine Design: The subunit and adjuvant approach. New York: Plenum Press (1995), 249-276.
6. Shi, Y., Hogen-Esch, H., Hem, S. L.: Change in the degree of adsorption of proteins by aluminium-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 20 (2002), 80-85.
7. Lehmann, H. G.: Influenza-Virus-Spaltvakzine: mit oder ohne Adjuvans? Die gelben Hefte 21 (1981), 76-80.
8. Ott, G., Barchfield, G. L., Chernoff, D., et al.: MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell, M. F., Newman, M. J. (eds): Vaccine Design: The subunit and adjuvant approach. New York: Plenum Press (1995), 277-296.
9. Ott, G., Radhakrishnan, R., Fang, J.-H., et al.: The adjuvant MF59: A 10-year perspective. In: O'Hagan, D. T. (ed): Methods in molecular medicine. Vaccine adjuvants: preparation methods and research protocols. Totowa, New York: Humana Press (2000), 211-228.
10. O'Hagan, D., Wack, A., Baudner, B., et al.: MF59 is the most potent adjuvant for flu vaccines. Poster presented at ICID Congress, Lisbon, June 2006.
11. De Donato, S., Granoff, D., Minutello, M., et al.: Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 (1999), 3094-3101.
12. Baldo, V., Menegon, T., Bonello, C., et al.: Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 (2001), 3472-3475.
13. Minutello, M., Senatore, F., Ceccinelli, C., et al.: Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 (1999), 99-104.
14. Baldo, V., Baldovin, T., Floreani, A., et al.: MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications Vaccine, 25 (2007), 3955-3961.
15. Baldo, V., Baldovin, T., Floreani, A., et al.: Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases. J Clin. Immunol. 27 (2007), 542-547.
16. Schweiger, B., Harder, H., Seiler, V., et al.: Erste Erfahrungen mit einem adjuvierten Influenzaimpfstoff bei onkologischen Patienten. ImpfDialog 1 (2001), 86-90.
17. Iorio, A. M., Francisci, D., Camilloni, B., et al.: Antibody responses and Hiv-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 21 (2003), 3629-3637.
18. Paschke, R., Pollok, M., Geiger, H., et al.: Increased immunogenicity with an MF59-adjuvanted influenza vaccine compared to a conventional sub-unit vaccine in renal transplant recipients. J Prevent. Med. Hyg. 44 (2003), 79-84.
19. [ 19] Podda, A., Del Giudice, G.: MF59-adjanted vaccines: increased immunogenecity with an optimal safety profile. Exp. Rev. Vaccines 2 (2003), 197-204.
20. Nicholson, K. G, Colegate, A. E., Podda, A., et al.: Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001), 1937-1943.
21. Stephenson, I., Nicholson, K.G., Colegate, A., et al.: Boosting immunity to influenza H5N1 with MF59 adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21 (2003), 1687-1693.
22. Stephenson, I., Bugarini, R., Nicholson, K. G., et al.: Cross-reactivity to highly pathogenic avian influenza H5N1 Viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191 (2005), 1210-1215.
23. Schultze, V., D'Agosto, V., Wack, A., et al.: Safety of MF59™ Adjuvant. Submitted for publication.